

North Central Cancer Treatment Group

N0321: Phase I/II Study of PS-341 in Combination with Paclitaxel, Carboplatin, and Concurrent Thoracic Radiation Therapy for Non-small Cell Lung Cancer (NSCLC)

Update 1 – February 11, 2005

Summary

- Editorial/administrative changes.

Replacement pages are included. Please incorporate into the protocol and keep this update with your protocol.

Title page: Reflects Update 1 and revised NCI version date.

Page 18: Section 7.11 (Protocol Treatment) has been revised to reflect the name change of Pepcid to **FAMOT** in order to be consistent with the use of the NCCTG drug abbreviations. Also, clarification has been made that Benadryl will be given along with RANIT, CIMET, or FAMOT.

Section 7.12 (Protocol Treatment), “Dosage in mg = (target AUC = 2) x (CrCl + 25)” has been deleted from the second column because the target AUC is determined by the dose level in Section 7.13. Reference to footnote #3 has been added to the first column for CBDCA.

Page 21: Section 7.41 (Protocol Treatment) has been revised to reflect the name change of Pepcid to **FAMOT** in order to be consistent with the use of the NCCTG drug abbreviations. Also, clarification has been made that Benadryl will be given along with RANIT, CIMET, or FAMOT.

Section 7.42 (Protocol Treatment) has been revised to add footnote #3 for consistency with Section 7.12. Reference to footnote #3 has been added to the first column for CBDCA.

Page 37: Section 15.1 (Drug Information), the e-mail address for obtaining the investigator brochure has been corrected.